TOPS System
Premia Spine, Ltd. · Decision date May 29, 2026
What did the FDA approve?
FDA records P220002/S009 as a supplement to PMA P220002, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 29, 2026.
FDA approval order statement
Approval for the addition of a new inserter (TOPS 2 inserter) and implant design variant (TOPS 2) to be included in the TOPS System
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Orthopedic
- Decision date
- May 29, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P220002/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Premia Spine, Ltd.
- Product code
- QWK
- Decision code
- APPR
- Decision date
- May 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, posterior spinal elements.
- Applicant
- Premia Spine, Ltd.
- Product code
- QWK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220002 · Original PMA
TOPS System
P220002/S009 received
Application receipt date recorded by FDA.
P220002/S010 · Related supplement
TOPS System
P220002/S009 · FDA decision
Normal 180 Day Track
P220002/S011 · Related supplement
TOPS System
Timeline entries are records held by MedtechLedger for P220002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TOPS SystemP220002 | Premia Spine, Ltd. | PMA approval | Jun 15, 2023 | FDA |
TOPS SystemP220002/S010 | Premia Spine, Ltd. | PMA supplement | Oct 29, 2025 | FDA |
TOPS SystemP220002/S011 | Premia Spine, Ltd. | PMA supplement | Sep 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Premia Spine, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7 Giborey Israel St., Ramat Poleg, Netanya, 4250407
Sources and methodology
- Original FDA record: P220002/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
